Nemolizumab Recombinant Human Monoclonal Antibody, Invitrogen™

Description

• Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles
• Store at 2 to 8 °C for one week
• Store at -20 to -80 °C for twelve months from the date of receipt
• Nemolizumab is a biosimilar that targets IL31RA
• IL-31 is a T cell cytokine that is preferentially produced by T helper type 2 cells
• IL-31 signals through a heterodimeric receptor composed of the IL-31 receptor (IL-31R) and the oncostatin M receptor (OSM)
• This receptor complex recruits JAK1, JAK2, Stat1, Stat3 and Stat5 signaling pathways, as well as the pi3 kinase/AKT cascade
• SHP-2 and Shc adapter molecules are also recruited and contribute to an increased activation of the MAP kinase pathway in response to IL-31
• Overexpression of IL-31 in mice results in pruritus and skin dermatitis resembling human atopic dermatitis (AD)
• Comparisons between skin from patients with AD and healthy skin showed IL-31R expression at higher levels on epidermal keratinocytes in AD samples
• Infiltrating cells, more numerous in skin from patients with AD compared with that of healthy individuals, expressed IL-31 mRNA
• IL-31 may participate in the cause of itch sensation and promote scratching behavior in NC/Nga mice with atopic dermatitis, and may represent a novel target for antipruritic drug development.